Protagonist Therapeutics Inc banner

Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 100 USD -2.55% Market Closed
Market Cap: $6.4B

EV/OCF

98.7
Current
1 327%
More Expensive
vs 3-y average of 6.9

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
98.7
=
Enterprise Value
$5.3B
/
Operating Cash Flow
$57.7m

Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.

EV/OCF
98.7
=
Enterprise Value
$5.3B
/
Operating Cash Flow
$57.7m

Valuation Scenarios

Protagonist Therapeutics Inc is trading above its 3-year average

If EV/OCF returns to its 3-Year Average (6.9), the stock would be worth $7.01 (93% downside from current price).

Statistics
Positive Scenarios
0/3
Maximum Downside
-93%
Maximum Upside
No Upside Scenarios
Average Downside
87%
Scenario EV/OCF Value Implied Price Upside/Downside
Current Multiple 98.7 $100
0%
3-Year Average 6.9 $7.01
-93%
Industry Average 15.1 $15.29
-85%
Country Average 16.7 $16.91
-83%

Forward EV/OCF
Today’s price vs future operating cash flow

Not enough data available to calculate forward EV/OCF

Peer Comparison

All Multiples
EV/OCF
P/E
All Countries
Close
Market Cap EV/OCF P/E
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
6.3B USD 98.7 -48.1
FR
Pharnext SCA
OTC:PNEXF
6T USD -211 715.8 -160 127.7
US
Abbvie Inc
NYSE:ABBV
351.3B USD 21.4 83.9
US
Amgen Inc
NASDAQ:AMGN
185.7B USD 22.8 24.1
US
Gilead Sciences Inc
NASDAQ:GILD
161.8B USD 17.3 19
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
109.3B USD 27.9 27.6
US
Epizyme Inc
F:EPE
94.1B EUR -531.8 -533.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.4B USD 11.6 17.6
NL
argenx SE
XBRU:ARGX
41.2B EUR 108.4 37.3
US
Seagen Inc
F:SGT
39.3B EUR -83.5 -61.8
AU
CSL Ltd
ASX:CSL
62.7B AUD 14.7 30.7
P/E Multiple
Earnings Growth PEG
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
Average P/E: 34.3
Negative Multiple: -48.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
83.9
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.1
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
19
16%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.6
19%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
14%
1.3
NL
argenx SE
XBRU:ARGX
37.3
30%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
AU
CSL Ltd
ASX:CSL
30.7
9%
3.4

Market Distribution

Higher than 96% of companies in the United States of America
Percentile
96th
Based on 9 518 companies
96th percentile
98.7
Low
0 — 11.7
Typical Range
11.7 — 23.6
High
23.6 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 11.7
Median 16.7
70th Percentile 23.6
Max 3 178 983.5

Protagonist Therapeutics Inc
Glance View

Market Cap
6.4B USD
Industry
Biotechnology

Protagonist Therapeutics Inc. stands as a pioneering player in the biopharmaceutical landscape, diligently orchestrating the journey from scientific discovery to therapeutic breakthroughs. Established with the vision to exploit the therapeutic potential of peptides, the company has carved a niche for itself by focusing on innovative peptide-based drug discovery and development. Their proprietary technology platform is designed to genetically engineer and optimize peptides aimed at treating a spectrum of diseases, notably in areas of unmet medical needs such as autoimmune conditions and rare genetic disorders. The fusion of cutting-edge biotechnology and seasoned expertise enables Protagonist to transform promising scientific concepts into viable medicines, paving the way for advancements in patient treatment options. Fueling its growth and revenue potential, Protagonist Therapeutics operates primarily through partnerships and collaborative alliances, as well as progressing its proprietary pipeline. By leveraging strategic collaborations with established pharmaceutical giants, the company garners funding, technological insights, and broader developmental capabilities. This collaborative synergy not only bolsters their research endeavors but also hastens the clinical development and eventual commercialization of their pipeline products. Their ability to secure partnerships and effectively progress their drug candidates through various clinical stages is critical to their financial model, converting scientific innovation into shareholder value and societal impact. The company continues to navigate the complexities of drug development with a steadfast focus on unlocking the therapeutic potential of peptides, aspiring to merge innovation with tangible health benefits.

PTGX Intrinsic Value
12.83 USD
Overvaluation 87%
Intrinsic Value
Price $100
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett